Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. (2019)
Attributed to:
Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.bcp.2019.03.009
PubMed Identifier: 30862505
Publication URI: http://europepmc.org/abstract/MED/30862505
Type: Journal Article/Review
Volume: 163
Parent Publication: Biochemical pharmacology
ISSN: 0006-2952